Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?

Medical Journal of Australia

Volumn 190, Issue 11, 2009, Pages 614-615

  Woods, Robyn L ^a   Tonkin, Andrew M ^a   Nelson, Mark R ^b   Britt, Helena C ^c   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFECT; EDITORIAL; EVIDENCE BASED PRACTICE; HEART PROTECTION; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROPHYLAXIS; TREATMENT CONTRAINDICATION; AGED; DOSE RESPONSE; METHODOLOGY; PRIMARY PREVENTION; TREATMENT OUTCOME;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 68349091656     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02587.x     Document Type: Editorial

References (17)

1. Diabetes Australia and Royal Australian College of General Practitioners. Diabetes management in general practice. Guidelines for type 2 diabetes 2008/9. Canberra: Diabetes Australia, 2008. (Diabetes Australia Publication NP 1055.) http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/ RACGPGuidelines/Diabetesmanagement/2008DiabetesManagementInGeneralPractice.pdf (accessed Apr 2009).
2. National Health and Medical Research Council. National evidence based guidelines for the management of type 2 diabetes mellitus. Part 5. Prevention and detection of macrovascular disease in type 2 diabetes. Canberra: NHMRC, 2004. http://www.nhmrc.gov.au/publications/synopses/-files/di11.pdf (accessed Apr 2009).
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172. (Pubitemid 34073943)
4. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; 27 Suppl 1: 72-73.
5. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 Suppl 2: 1-9.
6. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-708. (Pubitemid 30179400)
7. International Diabetes Federation. Global guideline for type 2 diabetes. Brussels: IDF, 2005. http://www.idf.org/home/index.cfm?node=1457 (accessed Apr 2009).
8. Donnan PT, Donnelly L, New JP, Morris AD. Derivation and validation of a prediction score for major coronary heart disease events in a UK type 2 diabetic population. Diabetes Care 2006; 29: 1231-1236. (Pubitemid 44125915)
9. Britt H, Miller GC, Henderson J, Bayram C. Patient-based substudies from BEACH: abstracts and research tools 1999-2006. General practice series no. 20. Canberra: Australian Institute of Health and Welfare, 2007. (AIHW Cat. No. GEP 20; abstract item 94.) http://www.aihw.gov.au/publications/index.cfm/title/10473 (accessed Apr 2009).
10. Britt H, Miller GC, Charles J, et al. General practice activity in Australia 2007-2008. General practice series no. 22. Canberra: Australian Institute of Health and Welfare, 2008. (AIHW Cat. No. GEP 22; abstract item 115.) http://www.aihw.gov.au/publications/index.cfm/title/10651 (accessed Apr 2009).
11. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
12. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-2141.
13. Swan N. Aspirin for the prevention of heart attack [radio transcript]. The health report. Radio National. Australian Broadcasting Corporation. 27 October 2008. http://www.abc.net.au/rn/healthreport/stories/2008/2399279.htm (accessed Apr 2009).
14. Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes [editorial]. JAMA 2008; 300: 2180-2181.
15. Farkouh ME, Fuster V. Diabetes and aspirin: beware of underpowered negative trials [editorial]. Nat Clin Pract Cardiovasc Med 2009; 6: 1.
16. ASCEND: A Study of Cardiovascular Events iN Diabetes. http://clinicaltrials.gov/ct2/show/NCT00135226?spons= %22University+of+Oxford%22&spons-ex=Y&rank=8 (accessed Apr 2009).
17. Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105-109.